Technical Analysis for BCLI - Brainstorm Cell Therapeutics Inc.

Grade Last Price % Change Price Change
grade A 9.08 6.82% 0.58
BCLI closed up 6.82 percent on Friday, June 5, 2020, on 1.75 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical BCLI trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
New 52 Week Closing High Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.
Biotechnology Biology Stem Cells Multiple Sclerosis Parkinson's Disease Amyotrophic Lateral Sclerosis Neurochemistry Neurodegenerative Diseases Neurodegenerative Disorders Adult Stem Cell Induced Stem Cells Mesenchymal Stem Cell Stem Cell Therapies For Neurodegenerative Diseases

Is BCLI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.0
52 Week Low 3.43
Average Volume 457,915
200-Day Moving Average 4.81
50-Day Moving Average 6.04
20-Day Moving Average 6.64
10-Day Moving Average 7.51
Average True Range 0.52
ADX 24.25
+DI 46.73
-DI 12.49
Chandelier Exit (Long, 3 ATRs ) 7.87
Chandelier Exit (Short, 3 ATRs ) 6.62
Upper Bollinger Band 8.79
Lower Bollinger Band 4.48
Percent B (%b) 1.07
BandWidth 64.94
MACD Line 0.68
MACD Signal Line 0.40
MACD Histogram 0.2737
Fundamentals Value
Market Cap 171.08 Million
Num Shares 18.8 Million
EPS -0.32
Price-to-Earnings (P/E) Ratio -28.38
Price-to-Sales 0.00
Price-to-Book 15.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.58
Resistance 3 (R3) 10.53 9.99 10.33
Resistance 2 (R2) 9.99 9.60 10.01 10.25
Resistance 1 (R1) 9.53 9.37 9.76 9.58 10.16
Pivot Point 8.99 8.99 9.10 9.01 8.99
Support 1 (S1) 8.53 8.60 8.76 8.58 8.00
Support 2 (S2) 7.99 8.37 8.01 7.91
Support 3 (S3) 7.53 7.99 7.83
Support 4 (S4) 7.58